Clinical Trial Update: Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

View source ↗

Summary

This document provides an update on the expanded access protocol for Viaskin Peanut (DBV712) in peanut-allergic children. The protocol is currently available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Viaskin Peanut (peanut epicutaneous immunotherapy patch)

Snippet

Sponsor: DBV Technologies | Conditions: Peanut Allergy | Status: AVAILABLE